Indian Health Activists Take Legal Action To Stop Patenting Of Gilead Hepatitis C Drug

“Indian health activists are seeking to prevent Gilead from patenting its new treatment for Hepatitis C in the country in a fresh battle over affordable access to medicine,” the Financial Times reports. “The Initiative for Medicines, Access & Knowledge in India said it had filed a ‘pre-grant’ application in Calcutta to block” Gilead’s patent application, a legal action that “follows previous spats in India over intellectual property on medicines including those for HIV and cancer [and] could open the way for local generic drug manufacturers to sell low-cost versions of the product domestically and export it to other low-income countries without strong patent protection laws,” the newspaper writes. “The legal action could stall for several years the granting of patents in India, which one generic drug manufacturer said could permit the production of low-cost equivalents over several years,” the Financial Times notes (Jack, 11/24).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.